预测小肾肿瘤的肿瘤学结局
研究纳入1998至2020年得克萨斯大学西南医学中心肾癌项目连续手术切除的小肾肿瘤(≤4 cm)患者,评估与转移相关的临床病理因素,包括前瞻性BAP1免疫组化及小鼠植入成瘤能力。3900例可评估肾切除术中1984例(51%)为小肾肿瘤,含1720例肾细胞癌;其中1576例无同时或异时性更大肾癌,37例(2%)发生转移。BAP1缺失在校正TNM分期和SSIGN评分后仍与无转移生存显著相关。
要点
- 小肾肿瘤中肾细胞癌发生转移的比例为2%(37/1576)。
- 转移的小肾肿瘤富集侵袭性形态学表型,小鼠植入成瘤率与大转移瘤相当。
- BAP1缺失在校正TNM分期和SSIGN评分后仍与无转移生存显著相关。
核心结论
- 研究识别了影响小肾肿瘤肾细胞癌患者无转移生存的临床病理特征,若经独立验证,这些数据应有助于患者预后判断并辅助主动监测策略。
研究设计与样本
- 研究为回顾性分析,纳入1998至2020年得克萨斯大学西南医学中心肾癌项目连续手术切除的小肾肿瘤(≤4 cm)患者,共3900例可评估肾切除术(来自3674例种族多样患者),其中1984例(51%)为小肾肿瘤,含1720例肾细胞癌。
- 研究评估了小肾肿瘤植入小鼠后的成瘤能力,作为肿瘤侵袭性的指标。
- 在临床实验室改进修正案(CLIA)实验室前瞻性进行BAP1免疫组化。
- 采用多变量Cox比例风险回归预测无转移生存。
主要发现
- 1720例小肾肿瘤肾细胞癌患者中,1576例无同时或异时性更大肾癌,其中37例(2%)发生转移。
- 转移的小肾肿瘤肾细胞癌显著富集侵袭性形态学表型,且小鼠植入成瘤率与大转移瘤相当。
- BAP1缺失在校正TNM分期和SSIGN评分后的多变量分析中仍与无转移生存显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most patients diagnosed with renal cancer today present with small renal masses (SRMs). Although these patients have a low risk of dying from their disease and many are followed with active surveillance protocols, a small subset of renal cell carcinomas (RCCs) behave aggressively. Knowledge regarding features of aggressive behavior would enable better adoption of active surveillance strategies among these patients. OBJECTIVE: We sought to improve prognostic models to predict metastasis-free survival after nephrectomy through focused analyses of clinicopathologic characteristics of SRMs associated with adverse outcomes. DESIGN, SETTING, AND PARTICIPANTS: We identified consecutive patients with surgically resected SRMs (≤4 cm) at the University of Texas Southwestern Kidney Cancer Program between 1998 and 2020. In addition, we evaluated the ability of SRMs to form tumors when implanted in mice, an indicator of tumor aggressiveness. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We examined the clinicopathologic factors associated with metastasis including prospectively performed BAP1 immunohistochemistry at our Clinical Laboratory Improvement Amendments laboratory. Multivariable Cox proportional hazard regression was used to predict metastasis-free survival. RESULTS AND LIMITATIONS: A total of 3900 evaluable nephrectomies (from 3674 ethnically diverse patients) were identified, of which 1984 (51%) were SRMs including 1720 RCC. Of these patients with RCC (SRMRCC), 1576 did not have synchronous or metachronous larger RCCs and among these, 37 (2%) developed metastases. SRMRCC that metastasized were significantly enriched for aggressive morphologic phenotypes and engrafted in mice at comparable rates as larger metastatic tumors. BAP1 loss remained significantly associated with metastasis-free survival after accounting for TNM (tumor-node-metastasis) stage and SSIGN (stage, size, grade, and necrosis) score in multivariable analysis. CONCLUSIONS: We identified clinicopathologic features that influence metastasis-free survival for patients with SRMRCC. If validated independently, these data should assist with patient prognosis and help with active surveillance strategies. PATIENT SUMMARY: We report the identification of features of aggressiveness in small renal tumors that influence the likelihood of metastases after surgery.
引用
- Kapur P, Zhong H, Araj E, et al. Predicting Oncologic Outcomes in Small Renal Tumors. Eur Urol Oncol. 2022. PMID: 36115820. doi:10.1016/j.euo.2022.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。